Regulatory milestones

ALK-Abello A/S (CSE:ALK-B) was up DKK26 to DKK441 on Friday after Merck & Co. Inc. (NYSE:MRK) said it submitted a BLA to FDA in January for its Grass Allergy Immunotherapy Tablet. Merck has exclusive North American rights from ALK-Abello, which markets the product as Grazax in Europe.